Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: Olmesartan medoxomil compared with losartan, valsartan, and irbesartan

PharmacoEconomics

Volumn 21, Issue 1, 2003, Pages 61-74

  Simons, W Robert ^a  

^a Global Health Economics and Outcomes Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; HYPERTENSION; LONG TERM CARE; MANAGED CARE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; HYPERTENSION; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; UNITED STATES;

EID: 0037232826     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321010-00005     Document Type: Article

References (19)

1. Anderson RN, Kochanek KD, Murphy SL. Report of final mortality statistics, 1995. Mort Vital Stat Rep 1997; 45 (11 Suppl. 2): 1-80
2. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275 (20): 1571-6
3. Neaton JD, Kuller L, Stamler J, et al. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, editors. Hypertension, pathophysiology, diagnosis, and management. 2nd ed. New York (NY): Raven Press, 1995: 127-44
4. Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155 (7): 701-9
5. Glasziou PP, Mitchell AS. Use of pharmacoeconomic data by regulatory authorities. In: Spilker B. Quality of life and pharmacoeconomic in clinical trials. Philadelphia (PA): Lippincott Raven, 1996: 1145
6. Hill S, Henry D, Pekarsky B, et al. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence: the Australian experience. Br J Clin Pharmacol 1997; 44 (5): 421-5
7. Care MoHaL-T. Ontario guidelines for drug submission and evaluation. Ontario: Care MortaL-T, 2000 Sep
8. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3 (5): 283-91
9. Physicians desk reference. 56 ed. Montvale (N J): Medical Economics, 2002
10. Dawber TR. Epidemiologic approaches to heart disease: the Framingham Study. Am J Public Health 1951; 41: 279-86
11. Hamilton M, Thompson E, Wisniewski T. The role of blood-pressure control in preventing complications of hypertension. Lancet 1964 Feb 1; I: 238
12. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335 (8693): 827-38
13. Simons R. Long term compliance with antihypertensive drug therapy in a managed care organization. Edinburgh, Scotland: ISPOR, 1999 Nov 11
14. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19 (6): 1446-57
15. Jonsson B, Johannesson M. Cost benefit of treating hypertension. Clin Exp Hypertens 1999; 21 (5-6): 987-97
16. Johannesson M, Jonsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992; 1 (4): 250-64
17. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293-8
18. Odell PM, Anderson KM, Kannel WB. New models for predicting cardiovascular events. J Clin Epidemiol 1994; 47 (6): 583-92
19. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16 (8): 569-75